At this meeting, the Committee will discuss biologics license application (BLA) 761248, for donanemab solution for intravenous infusion, submitted by Eli Lilly and Company, for the treatment of early symptomatic Alzheimer’s disease
Meeting Information and Materials: www.fda.gov/advisory-committe...
9 июн 2024